Sachin Jain, an analyst from Bank of America Securities, maintained the Buy rating on AstraZeneca. The associated price target remains the same with p16,500.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sachin Jain has given his Buy rating due to a combination of factors, including AstraZeneca’s attractive valuation and de-risked late-stage pipeline. He highlights that the current multiple around 16x 2027 earnings appears undemanding relative to the company’s mid-term outlook, which points to high single-digit sales growth and potential re-rating toward roughly 18x as key programs deliver.
Jain also underscores the strategic value of the CARDIO TTRansform trial for eplontersen in ATTR-CM, which benefits from robust design, larger scale than HELIOS-B, and supportive precedent data from Amvuttra. Together with multiple upcoming phase III readouts across oncology and cardiovascular franchises, and management’s confidence in pipeline execution, he views the risk-reward as favorable and maintains a £165 price target, unchanged from prior estimates.
In another report released on May 4, Bernstein also maintained a Buy rating on the stock with a £186.00 price target.